Joshua J. Meeks
Advanced in Upper Tract Urothelial Carcinoma (UTUC)

Dr. Joshua J. Meeks

Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
20 Years of Experience
Advanced in Upper Tract Urothelial Carcinoma (UTUC)
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Meeks is an Oncologist in Chicago, Illinois. Dr. Meeks has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery.

His clinical research consists of co-authoring 163 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Upper Tract Urothelial Carcinoma (UTUC).

Graduate Institution
Northwestern University Feinberg School Of Medicine, 2005
Specialties
Oncology
Licenses
Urology in IL
Board Certifications
American Board Of Urology - Urology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-150, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Meeks has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Bladder Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Other, Dietary supplement
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Pembrolizumab
Study Phase: Phase 1
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

163 Total Publications

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
Journal: The Journal of urology
Published: October 09, 2025
Similar Doctors
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Nicklas R. Pfanzelter
Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Nicklas R. Pfanzelter
Oncology

Endeavor Health Medical Group

777 Park W Ave, 
Highland Park, IL 
 (22.7 miles away)
847-432-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicklas Pfanzelter is an Oncologist in Highland Park, Illinois. Dr. Pfanzelter is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, and Urothelial Cancer. Dr. Pfanzelter is currently accepting new patients.

Shilajit D. Kundu
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Shilajit D. Kundu
Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Shilajit D. Kundu
Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
 (0.1 miles away)
312-695-8146
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shilajit Kundu is an Oncologist in Chicago, Illinois. Dr. Kundu has been practicing medicine for over 24 years and is rated as a Distinguished provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Prostate Cancer, Bladder Cancer, Familial Prostate Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Peter H. Odonnell
Hematology | Oncology
Distinguished in Upper Tract Urothelial Carcinoma (UTUC)
Dr. Peter H. Odonnell
Hematology | Oncology

The University Of Chicago

5841 S Maryland Ave, 
Chicago, IL 
 (7.4 miles away)
773-702-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Odonnell is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Odonnell is rated as an Advanced provider by MediFind in the treatment of Upper Tract Urothelial Carcinoma (UTUC). His top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Muscle Invasive Bladder Cancer, Prostate Cancer, and Familial Prostate Cancer. Dr. Odonnell is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meeks's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile